Annual General Meeting Webinar Information

RNS Number : 9623S

MGC Pharmaceuticals Limited

19 November 2021

 

MGC Pharmaceuticals Ltd.

Annual General Meeting Webinar Information

19 November 2021

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or the 'Company') is pleased to advise that it will be live streaming the Shareholder's 2021 Annual General Meeting (AGM) to be held at 1202 Hay Street, West Perth, Western Australia on Wednesday 24 November 2021 at 4.00pm AWST.

The formal business of the AGM will be hosted by MGC Pharma's Chairman, Mr Brett Mitchell, with other board members attending remotely by video link.

To register for the Webinar, please use the link below:

https://us02web.zoom.us/webinar/register/WN_6M7_PRNnSKCJqRrqHp-n4g

Upon registration to the Webinar participants are welcome to submit questions to the Company.  The Board will endeavour to answer questions relevant to the business of the meeting, as well as questions regarding the Company's operations. Please note that the video stream is view only and will not facilitate the casting of votes on Resolutions being put to the meeting.

Shareholders are strongly encouraged to vote prior to the meeting by following the instructions provided to them on the recently distributed proxy form.

Shareholders may also lodge their proxy votes online by following the steps below:

• Go to www.investorvote.com.au

• Enter the 6-digit control number: 186177

• You will then need your HIN/SRN and postcode to log-on

--Ends--

Authorised for release by the Executive Chairman, for further information please contact:

MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director [phone] [e-mail]	MGC Pharmaceuticals Ltd David Lim Company Secretary [phone] [e-mail]
UK Broker - Turner Pope Andy Thacker [phone] [e-mail]	UK PR Advisors - Tavistock Charles Vivian / Tim Pearson [phone] [e-mail]

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline. 

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

END

 

 

NOAFFSSAUEFSEDF